SCHEMBL264812

SCHEMBL264812

Cc1ccc2nccc(CNC(=O)c3ccc4nc(C(C)(C)C(F)(F)F)ccc4c3)c2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.39
PRKD3 O94806 1/20 0.38
PRKCG P05129 1/20 0.38
CDK1 P06493 1/20 0.38
CDK2 P24941 1/20 0.38
FLT4 P35916 1/20 0.38
FLT3 P36888 1/20 0.38
FRK P42685 1/20 0.38
CDK8 P49336 1/20 0.38
CSNK2A1 P68400 1/20 0.38
CDK5 Q00535 1/20 0.38
ACVR1 Q04771 1/20 0.38
MST1R Q04912 1/20 0.38
STK3 Q13188 1/20 0.38
PTK6 Q13882 1/20 0.38
PIM3 Q86V86 1/20 0.38
MINK1 Q8N4C8 1/20 0.38
HIPK4 Q8NE63 1/20 0.38
AURKB Q96GD4 1/20 0.38
PBK Q96KB5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL263771 0.91 EGLN1 (0.40) TRPV1CDK8ACVR1CLK4LMNA
SCHEMBL263858 0.91 SMN1; SMN2 (0.43) TRPV1LMNASMN1; SMN2HTTDDR1
SCHEMBL264386 0.85 SMN1; SMN2 (0.39) LMNASMN1; SMN2HTTDDR1KLKB1
SCHEMBL263302 0.83 EGLN1 (0.39) LMNASMN1; SMN2HTTDDR1KLKB1
SCHEMBL263695 0.79 SMN1; SMN2 (0.57) LMNASMN1; SMN2HTTKMT2AMAPT
SCHEMBL265347 0.79 NAMPT (0.43) TRPV1
SCHEMBL1840774 0.77 ROCK2 (0.45) LMNASMN1; SMN2HTTHDAC1KMT2A
SCHEMBL1840633 0.76 HPGD (0.41) LMNASMN1; SMN2HTTKMT2AKLKB1
SCHEMBL2008896 0.75 TP53 (0.38) LMNADDR1MAPTALDH1A1
SCHEMBL262685 0.72 PPARG (0.46) TRPV1LMNASMN1; SMN2HDAC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134004-B2 Substituted N-bicyclicalkyl bicycliccarboxyamide compounds PFIZER INC. (US) 2012-03-13 US disclosed
US-8134004-B2 Substituted N-bicyclicalkyl bicycliccarboxyamide compounds PFIZER INC. (US) 2012-03-13 US disclosed
US-8134004-B2 Substituted N-bicyclicalkyl bicycliccarboxyamide compounds PFIZER INC. (US) 2012-03-13 US disclosed
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS PFIZER INC 2009-10-08 US disclosed
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS PFIZER INC 2009-10-08 US disclosed
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS PFIZER INC 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS OPRL1, CNR1, TRPV1 TRPV1 3/4885PRKD3 3559/4885PRKCG 2571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.